No erosive progression revealed by MRI in rheumatoid arthritis patients treated with etanercept, even in patients with persistent MRI and clinical signs of joint inflammation.
Døhn, Uffe Møller; Skjødt, Henrik; Hetland, Merete Lund; Vestergaard, Aage; Møller, Jakob M; Knudsen, Lene Surland; Ejbjerg, Bo Jannik; Thomsen, Henrik S; Ostergaard, Mikkel.
; 26(11): 1857-61, 2007 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-17332974
Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
MRI evidence of persistent joint inflammation and progressive joint damage despite clinical remission during treatment of early rheumatoid arthritis.
Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction.
New learnings on the pathophysiology of RA from synovial biopsies.
The effects of tocilizumab on osteitis, synovitis and erosion progression in rheumatoid arthritis: results from the ACT-RAY MRI substudy.
Differentiation between early rheumatoid arthritis patients and healthy persons by conventional and dynamic contrast-enhanced magnetic resonance imaging.
Contrast-enhanced whole body joint MR imaging in rheumatoid patients on tumour necrosis factor-alpha agents: a pilot study to evaluate novel scoring system for MR synovitis.
Should imaging be a component of rheumatoid arthritis remission criteria? A comparison between traditional and modified composite remission scores and imaging assessments.
Imaging progression despite clinical remission in early rheumatoid arthritis patients after etanercept interruption.
A randomised controlled trial of etanercept and methotrexate to induce remission in early inflammatory arthritis: the EMPIRE trial.